The European Commission has approved the use of ocriplasmin for treating vitreomacular traction (VMT) in the European Union.
Ocriplasmin has been developed by ThromboGenics in collaboration with Novartis and will be sold under the brand name Jetrea. VMT is an age-related and progressive condition which could result in severe eye damage.
Amblyopia
Amblyopia is the loss of one eye''s ability to see details. Amblyopia is otherwise known as lazy eye.
Advertisement
The drug has been approved for treating VMT when it is associated with a macular hole with a diameter of 400 µm or less.
ThromboGenics will be paid €45 million by Alcon, a subsidiary unit of Novartis, with a similar payment to be made with the first sale of the drug. Around 250,000-300,000 patients in Europe are reported to suffer from VMT with the current treatment involving a 'watchful process' until the patient is eligible for surgery.
Source: Medindia
Source: Medindia
Clear the Blur-Tips to Boost Your Eye-Q
Eye problems may present as blurry vision or simply a minor headache, but they can affect your life in more ways than one. Here's a comprehensive yet compact guide to boost your eye-Q.
Advertisement
 Watery EyesExcess tearing may cause a sensation of watery eyes or result in tears falling down the cheek. Obstruction of tear drainage path can lead to stasis and is also a reason for watery eyes. | Advertisement
|
Eye Twitching - Blepharospasm
Uncontrolled muscle twitching occurs in this condition, though benign it may need further investigation and sometimes an injection of Botox can cures it.
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.